1.Incidence of Clostridioides difficile Infections in Republic of Korea:A Prospective Study With Active Surveillance vs. National Data From Health Insurance Review & Assessment Service
Jieun KIM ; Rangmi MYUNG ; Bongyoung KIM ; Jinyeong KIM ; Tark KIM ; Mi Suk LEE ; Uh Jin KIM ; Dae Won PARK ; Yeon-Sook KIM ; Chang-Seop LEE ; Eu Suk KIM ; Sun Hee LEE ; Hyun-Ha CHANG ; Seung Soon LEE ; Se Yoon PARK ; Hee Jung CHOI ; Hye In KIM ; Young Eun HA ; Yu Mi WI ; Sungim CHOI ; So Youn SHIN ; Hyunjoo PAI
Journal of Korean Medical Science 2024;39(12):e118-
Background:
Since the emergence of hypervirulent strains of Clostridioides difficile, the incidence of C. difficile infections (CDI) has increased significantly.
Methods:
To assess the incidence of CDI in Korea, we conducted a prospective multicentre observational study from October 2020 to October 2021. Additionally, we calculated the incidence of CDI from mass data obtained from the Health Insurance Review and Assessment Service (HIRA) from 2008 to 2020.
Results:
In the prospective study with active surveillance, 30,212 patients had diarrhoea and 907 patients were diagnosed with CDI over 1,288,571 patient-days and 193,264 admissions in 18 participating hospitals during 3 months of study period; the CDI per 10,000 patientdays was 7.04 and the CDI per 1,000 admission was 4.69. The incidence of CDI was higher in general hospitals than in tertiary hospitals: 6.38 per 10,000 patient-days (range: 3.25–12.05) and 4.18 per 1,000 admissions (range: 1.92–8.59) in 11 tertiary hospitals, vs. 9.45 per 10,000 patient-days (range: 5.68–13.90) and 6.73 per 1,000 admissions (range: 3.18–15.85) in seven general hospitals. With regard to HIRA data, the incidence of CDI in all hospitals has been increasing over the 13-year-period: from 0.3 to 1.8 per 10,000 patient-days, 0.3 to 1.6 per 1,000 admissions, and 6.9 to 56.9 per 100,000 population, respectively.
Conclusion
The incidence of CDI in Korea has been gradually increasing, and its recent value is as high as that in the United State and Europe. CDI is underestimated, particularly in general hospitals in Korea.
3.Lesion Detection Through MRI Postprocessing in Pathology-Proven Focal Cortical Dysplasia:Experience at a Single Institution in the Republic of Korea
Hyoshin SON ; Kyung-Il PARK ; Dae-Seop SHIN ; Jangsup MOON ; Soon-Tae LEE ; Keun-Hwa JUNG ; Ki-Young JUNG ; Kon CHU ; Sang Kun LEE
Journal of Clinical Neurology 2023;19(3):288-295
Background:
and Purpose Focal cortical dysplasia (FCD) is one of the most common causes of drug-resistant epilepsy, and necessitates a multimodal evaluation to ensure optimal surgical treatment. This study aimed to determine the supportive value of the morphometric analysis program (MAP) in detecting FCD using data from a single institution in Korea.
Methods:
To develop a standard reference for the MAP, normal-looking MRIs by two scanners that are frequently used in this center were chosen. Patients with drug-resistant epilepsy and FCD after surgery were candidates for the analysis. The three-dimensional T1-weighted MRI scans of the patients were analyzed as test cases using the MAP.
Results:
The MRI scans of 87 patients were included in the analysis. The radiologist detected abnormal findings correlated with FCD (RAD positive [RAD(+)]) in 34 cases (39.1%), while the MAP could detect FCD in 25.3% of cases. A combination of the MAP (MAP[+] cases) with interpretations by the radiologist increased the detection to 42.5% (37 cases). The lesion detection rate was not different according to the type of reference scanners except in one case. MAP(+)/RAD(-) presented in three cases, all of which had FCD type IIa. The detection rate was slightly higher using the same kind of scanner as a reference, but not significantly (35.0% vs. 22.4% p=0.26).
Conclusions
The results of postprocessing in the MAP for detecting FCD did not depend on the type of reference scanner, and the MAP was the strongest in detecting FCD IIa. We suggested that the MAP could be widely utilized without developing institutional standards and could become an effective tool for detecting FCD lesions.
4.A Case of Painful Legs and Moving Toes Syndrome in a Young Woman
Hyoeun BAE ; Dae-seop SHIN ; Mi-kyoung KANG ; Hyun Chang LEE ; Ki-Young JUNG
Journal of Sleep Medicine 2022;19(1):31-33
Painful legs and moving toes syndrome (PLMT) is a rare syndrome characterized by pain in the lower extremities and involuntary movements of single or multiple toes. A 29-year-old woman with lumbosacral intervertebral disc herniation complained of bilateral foot pain and involuntary toe movements for three months. This is the first case of PLMT in a young adult patient with a lumbosacral intervertebral disc herniation in Korea.
5.Lenalidomide for anemia correction in lower-risk del(5q) myelodysplastic syndrome patients of Asian ethnicity
Junshik HONG ; Yoo Jin LEE ; Sung Hwa BAE ; Jun Ho YI ; Sungwoo PARK ; Myung Hee CHANG ; Young Hoon PARK ; Shin Young HYUN ; Joo-Seop CHUNG ; Ji Eun JANG ; Joo Young JUNG ; So-Yeon JEON ; Seo-Young SONG ; Hawk KIM ; Dae Sik KIM ; Sung-Hyun KIM ; Min Kyoung KIM ; Sang Hoon HAN ; Seonyang PARK ; Yoo-Jin KIM ; Je-Hwan LEE ;
Blood Research 2021;56(2):102-108
Background:
To estimate real-world outcomes in East Asian populations, we conducted a nationwide retrospective analysis of the efficacy and safety of lenalidomide for del(5q) myelodysplastic syndrome (MDS) patients with transfusion-dependent anemia in Korea.
Methods:
Patients aged ≥19 years who had received lenalidomide for the treatment of lower-risk, red blood cell (RBC) transfusion-dependent del(5q) MDS were selected. A filled case report form (CRF) with information from electronic medical records was requested from members of the acute myeloid leukemia (AML)/MDS Working Party of the Korean Society of Hematology. All the CRFs were gathered and analyzed.
Results:
A total of 31 patients were included in this study. Of 28 evaluable patients, 19 (67.9%) achieved RBC transfusion independence (RBC-TI). Female sex and the development of thrombocytopenia during treatment were associated with achieving RBC-TI. The most common non-hematologic toxicities were pruritus, fatigue, and rashes. All non-hematologic toxicities of grades ≥3 were limited to rash (12.9%) and pruritus (6.5%). Dose reduction was required in 15 of the 19 responders (78.9%). The most common final stable dosing schedule for the responders was 5 mg once every other day (31.6%).
Conclusion
Lenalidomide efficacy and tolerability were similar in the Asian del(5q) MDS patients and western patients. Dose reduction during treatment was common, but it was not associated with inferior outcomes.
6.Lenalidomide for anemia correction in lower-risk del(5q) myelodysplastic syndrome patients of Asian ethnicity
Junshik HONG ; Yoo Jin LEE ; Sung Hwa BAE ; Jun Ho YI ; Sungwoo PARK ; Myung Hee CHANG ; Young Hoon PARK ; Shin Young HYUN ; Joo-Seop CHUNG ; Ji Eun JANG ; Joo Young JUNG ; So-Yeon JEON ; Seo-Young SONG ; Hawk KIM ; Dae Sik KIM ; Sung-Hyun KIM ; Min Kyoung KIM ; Sang Hoon HAN ; Seonyang PARK ; Yoo-Jin KIM ; Je-Hwan LEE ;
Blood Research 2021;56(2):102-108
Background:
To estimate real-world outcomes in East Asian populations, we conducted a nationwide retrospective analysis of the efficacy and safety of lenalidomide for del(5q) myelodysplastic syndrome (MDS) patients with transfusion-dependent anemia in Korea.
Methods:
Patients aged ≥19 years who had received lenalidomide for the treatment of lower-risk, red blood cell (RBC) transfusion-dependent del(5q) MDS were selected. A filled case report form (CRF) with information from electronic medical records was requested from members of the acute myeloid leukemia (AML)/MDS Working Party of the Korean Society of Hematology. All the CRFs were gathered and analyzed.
Results:
A total of 31 patients were included in this study. Of 28 evaluable patients, 19 (67.9%) achieved RBC transfusion independence (RBC-TI). Female sex and the development of thrombocytopenia during treatment were associated with achieving RBC-TI. The most common non-hematologic toxicities were pruritus, fatigue, and rashes. All non-hematologic toxicities of grades ≥3 were limited to rash (12.9%) and pruritus (6.5%). Dose reduction was required in 15 of the 19 responders (78.9%). The most common final stable dosing schedule for the responders was 5 mg once every other day (31.6%).
Conclusion
Lenalidomide efficacy and tolerability were similar in the Asian del(5q) MDS patients and western patients. Dose reduction during treatment was common, but it was not associated with inferior outcomes.
7.Patients' Preferences for Primary Colorectal Cancer Screening: A Survey of the National Colorectal Cancer Screening Program in Korea.
Young Hak CHO ; Dae Ho KIM ; Jae Myung CHA ; Yoon Tae JEEN ; Jeong Seop MOON ; Jin Oh KIM ; Sang Kil LEE ; Yu Kyung CHO ; Jong Pil IM ; Jae Young JANG ; Jeong Eun SHIN ; Soon Man YOON ; Yunho JUNG ; Eun Sun KIM ; Kang Nyeong LEE ; Soo Jeong CHO ; Yeol KIM ; Bo Young PARK
Gut and Liver 2017;11(6):821-827
BACKGROUND/AIMS: The adoption of colonoscopy as a primary colorectal cancer (CRC) screening technique has been argued for in Korea, without evidence of patient preferences. This study aimed to investigate patients’ preferences for the primary CRC screening test for the National Cancer Screening Program (NCSP). METHODS: Between June and August 2016, 414 individuals aged ≥50 years who participated in the NCSP were prospectively invited to complete a questionnaire regarding their preferences for the primary CRC screening test and the reasons for their selection. RESULTS: Among the 396 respondents who completed the questionnaire, 124 individuals (31.3%) preferred the fecal immunochemical test (FIT), whereas 272 individuals (68.7%) preferred colonoscopy. Elderly participants preferred the FIT (p < 0.001), whereas participants with a higher education level (p=0.030), a higher income level (p=0.009), or individuals with a family member (p=0.028) or acquaintance (p=0.013) with a history of CRC preferred colonoscopy. Only 12.9% of participants had a bad experience with a previous FIT; however, 39.3% of participants had a bad experience with a previous colonoscopy. CONCLUSIONS: Colonoscopy was preferred to FIT in a 2.2:1 ratio as the primary CRC screening test for the NCSP. Patients’ preference for colonoscopy should be considered for the NCSP in Korea.
Aged
;
Colonoscopy
;
Colorectal Neoplasms*
;
Early Detection of Cancer
;
Education
;
Humans
;
Korea*
;
Mass Screening*
;
Patient Preference
;
Prospective Studies
;
Surveys and Questionnaires
8.Nocturnal Restless Arms and Face Improved by Dopamine Agonist: Is It a Variant of Restless Legs Syndrome?.
Dae seop SHIN ; Seung Cheol LEE ; Soo A KIM ; Hyung Ki KIM ; Kwang Ik YANG
Journal of Sleep Medicine 2017;14(1):43-45
The symptoms of restless legs syndrome (RLS) usually involve legs and can extend to other body parts. However, isolated body parts other than leg have rarely been involved. A 32-year-old woman had abnormal sensations of both forearms and face during night, which caused a difficulty falling in sleep. The symptoms were relieved by shaking and rubbing. She experienced a clear benefit from pramipexole, but a recurrence of restlessness was followed in both arms subsequent to pramipexole withdrawal. Finally, she had been prescribed a dose of 0.375 mg, which was well tolerated for 6 years. We report a case of nocturnal restless arms and face without leg involvement, which was like RLS in terms of clinical criteria except lesion site.
Accidental Falls
;
Adult
;
Arm*
;
Dopamine Agonists*
;
Dopamine*
;
Female
;
Forearm
;
Human Body
;
Humans
;
Leg
;
Psychomotor Agitation
;
Recurrence
;
Restless Legs Syndrome*
;
Sensation
9.Evaluation of the Efficacy and Safety of DA-9601 versus Its New Formulation, DA-5204, in Patients with Gastritis: Phase III, Randomized, Double-Blind, Non-Inferiority Study.
Yoon Jin CHOI ; Dong Ho LEE ; Myung Gyu CHOI ; Sung Joon LEE ; Sung Kook KIM ; Geun Am SONG ; Poong Lyul RHEE ; Hwoon Yong JUNG ; Dae Hwan KANG ; Yong Chan LEE ; Si Hyung LEE ; Suck Chei CHOI ; Ki Nam SHIM ; Sang Yong SEOL ; Jeong Seop MOON ; Yong Woon SHIN ; Hyun Soo KIM ; Soo Teik LEE ; Jin Woong CHO ; Eun Kwang CHOI ; Oh Young LEE ; Jin Seok JANG
Journal of Korean Medical Science 2017;32(11):1807-1813
This study compared the efficacy of DA-9601 (Dong-A ST Co., Seoul, Korea) and its new formulation, DA-5204 (Dong-A ST Co.), for treating erosive gastritis. This phase III, randomized, multicenter, double-blind, non-inferiority trial randomly assigned 434 patients with endoscopically proven gastric mucosal erosions into two groups: DA-9601 3 times daily or DA-5,204 twice daily for 2 weeks. The final analysis included 421 patients (DA-5204, 209; DA-9601, 212). The primary endpoint (rate of effective gastric erosion healing) and secondary endpoints (cure rate of endoscopic erosion and gastrointestinal [GI] symptom relief) were assessed using endoscopy after the treatment. Drug-related adverse events (AEs), including GI symptoms, were also compared. At week 2, gastric healing rates with DA-5204 and DA-9601 were 42.1% (88/209) and 42.5% (90/212), respectively. The difference between the groups was −0.4% (95% confidence interval, −9.8% to 9.1%), which was above the non-inferiority margin of −14%. The cure rate of gastric erosion in both groups was 37.3%. The improvement rates of GI symptoms with DA-5204 and DA-9601 were 40.4% and 40.8%, respectively. There were no statistically significant differences between the two groups in both secondary endpoints. AEs were reported in 18 (8.4%) patients in the DA-5204 group and 19 (8.8%) in the DA-9601 group. Rates of AE were not different between the two groups. No serious AE or adverse drug reaction (ADR) occurred. These results demonstrate the non-inferiority of DA-5204 compared to DA-9601. DA-5204 is as effective as DA-9601 in the treatment of erosive gastritis. Registered randomized clinical trial at ClinicalTrials.gov (NCT02282670)
Artemisia
;
Double-Blind Method
;
Drug-Related Side Effects and Adverse Reactions
;
Endoscopy
;
Gastritis*
;
Humans
;
Seoul
10.Diagnostic Yield and Clinical Impact of Video Capsule Endoscopy in Patients with Chronic Diarrhea: A Korean Multicenter CAPENTRY Study.
Hyun Joo SONG ; Jeong Seop MOON ; Seong Ran JEON ; Jin Oh KIM ; Jinsu KIM ; Dae Young CHEUNG ; Myung Gyu CHOI ; Yun Jeong LIM ; Ki Nam SHIM ; Byong Duk YE ; Jae Hee CHEON ; Cheol Hee PARK ; Hyun Soo KIM ; Ji Hyun KIM ; Dong Kyung CHANG ; Jae Hyuk DO ; Kyeong Ok KIM ; Byung Ik JANG ; Sung Jae SHIN
Gut and Liver 2017;11(2):253-260
BACKGROUND/AIMS: In some cases, chronic diarrhea is unexplained, and small bowel disorders may be one of the causes. The aim of this study was to assess the diagnostic yield and clinical impact of video capsule endoscopy (VCE) in patients with chronic diarrhea. METHODS: We retrospectively analyzed records from October 2002 to August 2013 in the VCE nationwide database registry (n=2,964). Ninety-one patients from 15 medical centers (60 males and 31 females; mean age, 47±19 years) were evaluated for VCE as a result of chronic diarrhea. RESULTS: The duration of chronic diarrhea was 8.3±14.7 months. The positive diagnostic yield of VCE was 42.9% (39/91). However, 15.4% (14/91) exhibited an inconsistent result, and 41.8% (38/91) were negative. Abnormal findings consistent with chronic diarrhea included erosions/aphthous ulcers (19.8%), ulcers (17.6%), mucosal erythema (3.3%), edema (1.1%), and luminal narrowing (1.1%). The most common diagnoses were functional diarrhea associated with irritable bowel syndrome in 37 patients (40.7%) and Crohn’s disease in 18 patients (19.8%). After VCE examination, the diagnosis was changed in 34.1% of the patients (31/91). Hematochezia (odds ratio [OR], 8.802; 95% confidence interval [CI], 2.126 to 36.441) and hypoalbuminemia (OR, 4.811; 95% CI, 1.241 to 18.655) are predictive factors of a positive diagnostic yield. CONCLUSIONS: VCE had a favorable diagnostic yield and clinical impact on the management of patients with chronic diarrhea.
Capsule Endoscopy*
;
Diagnosis
;
Diarrhea*
;
Edema
;
Erythema
;
Female
;
Gastrointestinal Hemorrhage
;
Humans
;
Hypoalbuminemia
;
Irritable Bowel Syndrome
;
Male
;
Phenobarbital
;
Retrospective Studies
;
Ulcer

Result Analysis
Print
Save
E-mail